Viacyte is one of the most exciting biotechs in the stem cells for diabetes space. Dr. Kevin D’Amour, Director of Stem Cell Research at Viacyte, gave an excellent, extremely interesting talk Friday morning: Developing an Encapsulated Stem Cell Therapy for Diabetes. Viacyte talk In the talk, Dr. D’Amour gave a very detailed description of their […]
We’ve all been closely following Geron and its work on ES cells. This morning there was a fantastic session here at the ASGCT meeting in Seattle on Clinical Trials on Stem Cells. Talk by Geron One of the speakers was Geron VP, Jane Lebkoswki, PhD: Development of Human Embryonic Stem Cell-Based Therapies for Treatment of
Stem Cell Clinical Trials Part I: Geron VP Lebkoswki speaking today in Seattle Read More »
Email me your job opening if you are an employer and I’ll post it for free. If you are a job seeker, email me your info and I’ll post that for free. Job Openings 2013 for stem cells. Are you a grad student wrapping up your PhD in the next year or so? Have
The best talk today was the keynote address by Dr. George Daley focused mostly on iPS cells. Dr. Daley is one of the world’s experts on iPS cells and pluripotent stem cells more generally. He covered many interesting elements of the iPS cell field including the genetic mutations that seem to occur during the reprogramming
Summary of George Daley talk on iPS cells today in Seattle Read More »
There were three talks today on iPS cells here at the American Society for Gene and Cell Therapy meeting or ASGCT meeting in Seattle. Dr. James Ellis made the interesting case that it may be preferable to make iPS cells using genetic methods (while everyone else seems to be saying that non-genetic methods will be better).
News on iPS cells from some top scientists at ASGCT meeting today Read More »
This past week was a wacky and wild one for the stem cell field. All kinds of crazy things happened all in one week. What does it all mean? Stem cells the new steroids for sports? Reports surface this week that NY Yankees pitcher Bartolo Colon, had received a non-FDA approved stem cell treatment for
A crazy week for stem cells: what the heck does it all mean? Read More »
Today is Friday the 13th, which is supposed to be bad luck, and it seems to be a bad luck day for iPS cells. A paper came out today in Nature that will be highly upsetting for anyone hoping that iPS cells can follow a fairly direct path to the clinic. The paper from Yang
Friday the 13th for iPS cells Read More »
Yesterday I ran a cancer stem cells meeting here at UC Davis School of Medicine. We had some great speakers and over 150 participants including our outstanding keynote speaker, Dr. Jeremy Rich, Director of Stem Cell Research at the Cleveland Clinic. One of the ideas percolating through the meeting was that during cancer development, there
Cancer stem cells and iPS cells Read More »
Why invest in stem cells? Ideas are the foundation of stem cell research, but funding makes those ideas a reality. We talk a lot about governmental funding of stem cell research through CIRM and NIH. The funding from these agencies is essential and will undoubtedly lead to new treatments and cures, possibly for millions of
Why invest in stem cells? Progress, Patients, and Patents Read More »
Since Yamanaka’s discovery of iPS cells first in mouse and then in human cells 5 years ago, both made using viral transduction, a host of new methods to make iPS cells have been reported. These methods are quite diverse, ranging from transposons, to recombinant proteins, to plasmids, and to RNA. Often times these new approaches
Why miRNA iPS cells might be the ticket: an A+ paper Read More »